STOCK TITAN

[Form 4] CapsoVision, Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Michele Harari, a director of CapsoVision, Inc. (CV), reported changes in her beneficial ownership related to transactions dated 09/15/2025. The filing shows a disposition of 56,156 shares of common stock and an acquisition of 2,887 Restricted Stock Units (RSUs), each RSU representing the contingent right to one share. The RSUs were granted on 09/15/2025, carry a $0 acquisition price, and are scheduled to vest on December 31, 2025. The form notes earlier reporting of 187,000 shares on a Form 3 (filed July 1, 2025) and states those amounts reflect a 1-for-3.33 reverse stock split effected July 2, 2025 in connection with the issuer's IPO. The Form 4 was signed by Attorney-in-Fact on 09/17/2025.

Michele Harari, amministratrice di CapsoVision, Inc. (CV), ha riferito cambiamenti nella sua proprietà beneficiaria relativi a operazioni datate 09/15/2025. Il deposito mostra una cessione di 56.156 azioni ordinarie e un'acquisizione di 2.887 Restricted Stock Units (RSU), ciascuna RSU rappresentando il diritto condizionato a una azione. Le RSU sono state concesse il 09/15/2025, hanno un prezzo di acquisizione pari a 0 e dovranno maturare entro il 31 dicembre 2025. Il modulo segnala una precedente dichiarazione di 187.000 azioni sul Form 3 (depositato il 01/07/2025) e afferma che tali importi riflettono una scissione azionaria inversa di 1 per 3,33 effettuata il 02/07/2025 in relazione all’IPO dell’emittente. Il Form 4 è stato firmato dall’Attorney-in-Fact il 09/17/2025.

Michele Harari, directora de CapsoVision, Inc. (CV), informó cambios en su propiedad beneficiaria relacionados con transacciones fechadas el 15/09/2025. La presentación muestra una disposición de 56,156 acciones ordinarias y una adquisición de 2,887 Restricted Stock Units (RSUs), cada RSU representa el derecho contingente a una acción. Las RSU fueron concedidas el 15/09/2025, llevan un precio de adquisición de 0 y están previstas para vestirse el 31 de diciembre de 2025. El formulario señala una declaración anterior de 187,000 acciones en el Formulario 3 (presentado el 01/07/2025) y indica que esas cantidades reflejan una división inversa de acciones de 1 por 3,33 realizada el 02/07/2025 en relación con la IPO del emisor. El Formulario 4 fue firmado por el Attorney-in-Fact el 17/09/2025.

Michele Harari는 CapsoVision, Inc. (CV)의 이사로서 2025-09-15에 날짜를 가진 거래와 관련된 수익 보유 지분 변화가 보고되었습니다. 접수 서류에는 56,156주 주식 처분2,887 Restricted Stock Units (RSU)의 취득이 기재되어 있으며, 각 RSU는 주식 1주에 대한 조건부 권리를 나타냅니다. RSU는 2025-09-15에 부여되었고 취득 가격은 0이며 2025-12-31에 귀속될 예정입니다. 양식은 2025-07-01에 제출된 Form 3에서 187,000주의 이전 보고를 지적하고, 이 수치가 발행인의 IPO와 관련하여 2025-07-02에 실행된 1대 3.33의 역분할을 반영한다고 명시합니다. Form 4는 2025-09-17에 Attorney-in-Fact가 서명했습니다.

Michele Harari, administratrice de CapsoVision, Inc. (CV), a signalé des changements dans sa propriété bénéficiaire liés à des transactions datées du 15/09/2025. Le dossier indique une cession de 56 156 actions ordinaires et une acquisition de 2 887 Restricted Stock Units (RSU), chaque RSU représentant le droit conditionnel à une action. Les RSU ont été accordées le 15/09/2025, portent un prix d’acquisition de 0 et doivent vestir le 31 décembre 2025. Le formulaire mentionne une déclaration antérieure de 187 000 actions sur le Formulaire 3 (déposé le 01/07/2025) et indique que ces montants reflètent une scission inverse de 1 pour 3,33 réalisée le 02/07/2025 dans le cadre de l’IPO de l’émetteur. Le Formulaire 4 a été signé par l’Attorney-in-Fact le 17/09/2025.

Michele Harari, Direktorin von CapsoVision, Inc. (CV), berichtete über Änderungen in ihrem wirtschaftlich berechtigten Eigentum in Zusammenhang mit Transaktionen vom 15.09.2025. Die Einreichung zeigt eine Veräußerung von 56.156 Stammaktien und den Erwerb von 2.887 Restricted Stock Units (RSUs), wobei jede RSU das bedingte Recht auf eine Aktie darstellt. Die RSUs wurden am 15.09.2025 gewährt, sie haben keinen Anschaffungspreis (0) und sollen am 31.12.2025 vesten. Das Formular vermerkt eine frühere Meldung von 187.000 Aktien im Form 3 (eingereicht am 01.07.2025) und erläutert, dass diese Beträge eine 1-für-3,33-Split widerspiegeln, die am 02.07.2025 im Zusammenhang mit dem IPO des Emittenten durchgeführt wurde. Das Form 4 wurde am 17.09.2025 vom Attorney-in-Fact unterzeichnet.

ميشيل هاراري، مديرة في CapsoVision, Inc. (CV)، أبلغت عن تغيّر في الملكية المستفيدة مرتبط بصفقات مؤرخة في 15/09/2025. يُظهر الملف تصرفاً في 56,156 سهماً عادياً واكتساب 2,887 وحدة أسهم مقيدة (RSUs)، حيث تمثل RSU الواحدة حقاً مشروطاً في سهم واحد. تم منح RSU في 15/09/2025 وتبلغ تكلفة الاستحواذ عليها 0، ومن المقرر أن تتأهل في 31 ديسمبر 2025. يذكر النموذج إخطاراً سابقاً لـ 187,000 سهم في النموذج 3 (المقدم في 01/07/2025) ويشير إلى أن هذه الأرقام تعكس تقسيم عكسي للسهم بنسبة 1 مقابل 3.33 تم تنفيذه في 02/07/2025 فيما يتعلق بطرح الإصدار للشركة. تم توقيع النموذج 4 من قبل المحامي الوكيل في 17/09/2025.

Michele Harari,CapsoVision, Inc.(CV)的董事,报告了与日期为 2025-09-15 的交易相关的受益所有权变动。文件显示处置 56,156 股普通股,以及取得 2,887 个受限股票单位(RSUs),每个 RSU 代表对一股的或有权利。RSU 于 2025-09-15 授予,取得价格为 0,计划于 2025-12-31 授予归属。表格提到在 2025-07-01 提交的 Form 3 中此前披露 187,000 股,并表示这些数字反映了在 2025-07-02 为发行人 IPO 实施的 1 比 3.33 的反向分拆。Form 4 于 2025-09-17 由 Attorney-in-Fact 签署。

Positive
  • RSU grant aligns director compensation with shareholder outcomes by vesting on December 31, 2025
  • Filing includes reverse split explanation, clarifying prior reported balances
Negative
  • Director disposed of 56,156 common shares, reducing direct holdings
  • Sale price for the disposed shares is not disclosed in this Form 4

Insights

TL;DR: Director sold a material block of shares and received a modest RSU grant that vests year-end.

From a governance and disclosure perspective, the filing records a significant disposition of 56,156 common shares and the simultaneous grant of 2,887 RSUs to a director. The sale reduces the director's direct holdings while the RSUs align future compensation with shareholder value upon vesting. The reverse split disclosure clarifies prior reported balances; no price per share is stated for the sale in this filing and no other compensatory terms or acceleration provisions are disclosed. Overall, this is a routine Section 16 disclosure of insider activity with clear vesting timing for the RSUs.

TL;DR: Transaction is a standard insider reporting event with scheduled vesting, not indicating immediate governance change.

The report indicates the reporting person is a director and documents both a disposal and an equity award. The RSUs are time-based with a specified vest date of December 31, 2025, which is typical for retention-based awards. The filing properly notes the prior Form 3 balance adjusted for the issuer's 1-for-3.33 reverse split. There is no disclosure here of any related-party transaction, accelerated vesting, or change in board status. Materiality for shareholders is limited to transparency on insider holdings.

Michele Harari, amministratrice di CapsoVision, Inc. (CV), ha riferito cambiamenti nella sua proprietà beneficiaria relativi a operazioni datate 09/15/2025. Il deposito mostra una cessione di 56.156 azioni ordinarie e un'acquisizione di 2.887 Restricted Stock Units (RSU), ciascuna RSU rappresentando il diritto condizionato a una azione. Le RSU sono state concesse il 09/15/2025, hanno un prezzo di acquisizione pari a 0 e dovranno maturare entro il 31 dicembre 2025. Il modulo segnala una precedente dichiarazione di 187.000 azioni sul Form 3 (depositato il 01/07/2025) e afferma che tali importi riflettono una scissione azionaria inversa di 1 per 3,33 effettuata il 02/07/2025 in relazione all’IPO dell’emittente. Il Form 4 è stato firmato dall’Attorney-in-Fact il 09/17/2025.

Michele Harari, directora de CapsoVision, Inc. (CV), informó cambios en su propiedad beneficiaria relacionados con transacciones fechadas el 15/09/2025. La presentación muestra una disposición de 56,156 acciones ordinarias y una adquisición de 2,887 Restricted Stock Units (RSUs), cada RSU representa el derecho contingente a una acción. Las RSU fueron concedidas el 15/09/2025, llevan un precio de adquisición de 0 y están previstas para vestirse el 31 de diciembre de 2025. El formulario señala una declaración anterior de 187,000 acciones en el Formulario 3 (presentado el 01/07/2025) y indica que esas cantidades reflejan una división inversa de acciones de 1 por 3,33 realizada el 02/07/2025 en relación con la IPO del emisor. El Formulario 4 fue firmado por el Attorney-in-Fact el 17/09/2025.

Michele Harari는 CapsoVision, Inc. (CV)의 이사로서 2025-09-15에 날짜를 가진 거래와 관련된 수익 보유 지분 변화가 보고되었습니다. 접수 서류에는 56,156주 주식 처분2,887 Restricted Stock Units (RSU)의 취득이 기재되어 있으며, 각 RSU는 주식 1주에 대한 조건부 권리를 나타냅니다. RSU는 2025-09-15에 부여되었고 취득 가격은 0이며 2025-12-31에 귀속될 예정입니다. 양식은 2025-07-01에 제출된 Form 3에서 187,000주의 이전 보고를 지적하고, 이 수치가 발행인의 IPO와 관련하여 2025-07-02에 실행된 1대 3.33의 역분할을 반영한다고 명시합니다. Form 4는 2025-09-17에 Attorney-in-Fact가 서명했습니다.

Michele Harari, administratrice de CapsoVision, Inc. (CV), a signalé des changements dans sa propriété bénéficiaire liés à des transactions datées du 15/09/2025. Le dossier indique une cession de 56 156 actions ordinaires et une acquisition de 2 887 Restricted Stock Units (RSU), chaque RSU représentant le droit conditionnel à une action. Les RSU ont été accordées le 15/09/2025, portent un prix d’acquisition de 0 et doivent vestir le 31 décembre 2025. Le formulaire mentionne une déclaration antérieure de 187 000 actions sur le Formulaire 3 (déposé le 01/07/2025) et indique que ces montants reflètent une scission inverse de 1 pour 3,33 réalisée le 02/07/2025 dans le cadre de l’IPO de l’émetteur. Le Formulaire 4 a été signé par l’Attorney-in-Fact le 17/09/2025.

Michele Harari, Direktorin von CapsoVision, Inc. (CV), berichtete über Änderungen in ihrem wirtschaftlich berechtigten Eigentum in Zusammenhang mit Transaktionen vom 15.09.2025. Die Einreichung zeigt eine Veräußerung von 56.156 Stammaktien und den Erwerb von 2.887 Restricted Stock Units (RSUs), wobei jede RSU das bedingte Recht auf eine Aktie darstellt. Die RSUs wurden am 15.09.2025 gewährt, sie haben keinen Anschaffungspreis (0) und sollen am 31.12.2025 vesten. Das Formular vermerkt eine frühere Meldung von 187.000 Aktien im Form 3 (eingereicht am 01.07.2025) und erläutert, dass diese Beträge eine 1-für-3,33-Split widerspiegeln, die am 02.07.2025 im Zusammenhang mit dem IPO des Emittenten durchgeführt wurde. Das Form 4 wurde am 17.09.2025 vom Attorney-in-Fact unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Harari Michele

(Last) (First) (Middle)
C/O CAPSOVISION, INC.
18805 COX AVENUE, SUITE 250

(Street)
SARATOGA CA 95070

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CapsoVision, Inc [ CV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 56,156 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (RSU) (2) 09/15/2025 A 2,887 (3) (3) Common Stock 2,887 $0 2,887 D
Explanation of Responses:
1. The reporting person previously reported 187,000 common stock on a Form 3 filed July 1, 2025. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split of the Issuer's common stock effected by the Issuer on July 2, 2025 in connection with its initial public offering.
2. Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
3. These RSUs are scheduled to vest on December 31, 2025
Remarks:
/s/ Kang-Huai (Johnny) Wang, Attorney-in-Fact for Michele Harari 09/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
CapsoVision, Inc.

NASDAQ:CV

CV Rankings

CV Latest News

CV Latest SEC Filings

CV Stock Data

219.84M
5.25M
40.69%
0.05%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
SARATOGA